The Role of pharmacokinetics and pharmacodynamics in early drug development with reference to the cyclin-dependent kinase (Cdk) inhibitor - roscovitine

Sultan Qaboos University Medical Journal

Volumn 11, Issue 2, 2011, Pages 165-178

  Hassan, Moustapha ^a,b   Sallam, Hatem ^a   Hassan, Zuzana ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Agedependent kinetics; Anticancer drugs; Cdk inhibitor; Pharmacodynamics; Pharmacokinetics; Roscovitine; Toxicity

Indexed keywords

PROTOZOA; RATTUS;

EID: 79957949875     PISSN: 2075051X     EISSN: 20750528     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Lin JH, Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997; 49:403-49.
2. Meibohm B, Derendorf H. Pharmacokinetic/ pharmacodynamic studies in drug product development. J Pharm Sci 2002; 91:18-31.
3. Holford NH. Target concentration intervention: Beyond Y2K. Br J Clin Pharmacol 2001; 52:55-9.
4. Bjorkman S. Prediction of cytochrome p450- mediated hepatic drug clearance in neonates, infants and children:How accurate are available scaling methods? Clin Pharmacokinet 2006; 45:1-11.
5. Bjorkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: Theophylline and midazolam as model drugs. Br J Clin Pharmacol 2005; 59:691-704.
6. Domingo JL. Cobalt in the environment and its toxicological implications. Rev Environ Contam Toxicol 1989; 108:105-32.
7. Malumbres M, Barbacid M. Mammalian cyclindependent kinases. Trends Biochem Sci 2005; 30:630-41.
8. Perez de Castro I, de Carcer G, Malumbres M. A census of mitotic cancer genes: New insights into tumor cell biology and cancer therapy. Carcinogenesis 2007; 28:899-912.
9. Strock CJ, Park JI, Nakakura EK, Bova GS, Isaacs JT, Ball DW, et al. Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res 2006; 66:7509-15.
10. Goodyear S, Sharma MC. Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5. Exp Mol Pathol 2007; 82:25-32.
11. Zhang Q, Ahuja HS, Zakeri ZF, Wolgemuth DJ. Cyclin-dependent kinase 5 is associated with apoptotic cell death during development and tissue remodeling. Dev Biol 1997; 183:222-33.
12. Hakem A, Sasaki T, Kozieradzki I, Penninger JM. The cyclin-dependent kinase Cdk2 regulates thymocyte apoptosis. J Exp Med 1999; 189:957-68.
13. Hiromura K, Pippin JW, Blonski MJ, Roberts JM, Shankland SJ. The subcellular localization of cyclin dependent kinase 2 determines the fate of mesangial cells: Role in apoptosis and proliferation. Oncogene 2002; 21:1750-8.
14. Cruz JC, Tsai LH. A Jekyll and Hyde kinase: Roles for Cdk5 in brain development and disease. Curr Opin Neurobiol 2004; 14:390-4.
15. Dhavan R, Tsai LH. A decade of CDK5. Nat Rev Mol Cell Biol 2001; 2:749-59.
16. Angelo M, Plattner F, Giese KP. Cyclin-dependent kinase 5 in synaptic plasticity, learning and memory. J Neurochem 2006; 99:353-70.
17. Bibb JA. Role of Cdk5 in neuronal signaling, plasticity, and drug abuse. Neurosignals 2003; 12:191-9.
18. Nguyen C, Bibb JA. Cdk5 and the mystery of synaptic vesicle endocytosis. J Cell Biol 2003; 163:697-9.
19. Tomizawa K, Ohta J, Matsushita M, Moriwaki A, Li ST, Takei K, et al. Cdk5/p35 regulates neurotransmitter release through phosphorylation and downregulation of P/Q-type voltage-dependent calcium channel activity. J Neurosci 2002; 22:2590-7.
20. Canduri F, Perez PC, Caceres RA, de Azevedo WF, Jr. CDK9 a potential target for drug development. Med Chem 2008; 4:210-8.
21. Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002; 23:417-25.
22. De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH. Inhibition of cyclin-dependent kinases by purine analogues: Crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 1997; 243:518-26.
23. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997; 243:527-36.
24. Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, Baratte B, et al. Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 2005; 280:31208-19.
25. Tang L, Li MH, Cao P, Wang F, Chang WR, Bach S, et al. Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. J Biol Chem 2005; 280:31220-9.
26. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002; 102:463-8.
27. Raynaud FI, Fischer PM, Nutley BP, Goddard PM, Lane DP, Workman P. Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. Mol Cancer Ther 2004; 3:353-62.
28. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003; 13:41-7.
29. Zhang GJ, Safran M, Wei W, Sorensen E, Lassota P, Zhelev N, et al. Bioluminescent imaging of Cdk2 inhibition in vivo. Nat Med 2004; 10:643-8.
30. Krude T. Initiation of human DNA replication in vitro using nuclei from cells arrested at an initiationcompetent state. J Biol Chem 2000; 275:13699-707.
31. Matsumoto Y, Hayashi K, Nishida E. Cyclindependent kinase 2 (Cdk2) is required for centrosome duplication in mammalian cells. Curr Biol 1999; 9:429-32.
32. Sirri V, Hernandez-Verdun D, Roussel P. Cyclindependent kinases govern formation and maintenance of the nucleolus. J Cell Biol 2002; 15:969-81.
33. Wesierska-Gadek J, Gueorguieva M, Horky M. Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. Mol Cancer Ther 2005; 4:113-24.
34. Wesierska-Gadek J, Wandl S, Kramer MP, Pickem C, Krystof V, Hajek SB. Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells. J Cell Biochem 2008; 105:1161-71.
35. Lacrima K, Valentini A, Lambertini C, Taborelli M, Rinaldi A, Zucca E, et al. In vitro activity of cyclindependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann Oncol 2005; 16:1169-76.
36. Mohapatra S, Chu B, Zhao X, Pledger WJ. Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res 2005; 65:7717-23.
37. Kim EH, Kim SU, Shin DY, Choi KS. Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 2004; 23:446-56.
38. Alvi AJ, Austen B, Weston VJ, Fegan C, MacCallum D, Gianella-Borradori A, et al. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood 2005; 105:4484-91.
39. Wesierska-Gadek J, Gueorguieva M, Horky M. Dual action of cyclin-dependent kinase inhibitors: Induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin. Pol J Pharmacol 2003; 55:895-902.
40. Meijer L, Bettayeb K, Galons H. Roscovitine (CYC202, Seliciclib). In: Smith PJ and Yue E, Eds. Monographs on Enzyme inhibitors. CDK Inhibitors and their Potential as Anti-Tumor Agents. Colchester: CRC Press, Taylor & Francis, 2006. Pp.187-226.
41. Lu W, Chen L, Peng Y, Chen J. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 2001; 20:3206-16.
42. Abal M, Bras-Goncalves R, Judde JG, Fsihi H, De Cremoux P, Louvard D, et al. Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line. Oncogene 2004; 23:1737-44.
43. Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L, et al. Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res 2008; 68:7966-74.
44. Raynaud FI, Whittaker SR, Fischer PM, McClue S, Walton MI, Barrie SE, et al. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 2005; 11:4875-87.
45. Payton M, Chung G, Yakowec P, Wong A, Powers D, Xiong L, et al. Discovery and evaluation of dual CDK1 and CDK2 inhibitors. Cancer Res 2006; 6:4299-308.
46. Tirado OM, Mateo-Lozano S, Notario V. Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo. Cancer Res 2005; 65:9320-7.
47. Iurisci I, Filipski E, Reinhardt J, Bach S, Gianella-Borradori A, Iacobelli S, et al. Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res 2006; 66:10720-8.
48. Maggiorella L, Deutsch E, Frascogna V, Chavaudra N, Jeanson L, Milliat F, et al. Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo. Cancer Res 2003; 63:2513-7.
49. Vita M, Meurling L, Pettersson T, Cruz-Siden M, Siden A, Hassan M. Analysis of roscovitine using novel high performance liquid chromatography and UV-detection method: pharmacokinetics of roscovitine in rat. J Pharm Biomed Anal 2004; 34:425-31.
50. Vita M, Abdel-Rehim M, Olofsson S, Hassan Z, Meurling L, Siden A, et al. Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat. Eur J Pharm Sci 2005; 25:91-103.
51. Gherardi D, D'Agati V, Chu TH, Barnett A, Gianella-Borradori A, Gelman IH, et al. Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. J Am Soc Nephrol 2004; 15:1212-22.
52. Nutley BP, Raynaud FI, Wilson SC, Fischer PM, Hayes A, Goddard PM, et al. Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. Mol Cancer Ther 2005; 4:125-39.
53. De la Motte S, Gianella-Borradori A. Pharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects. Int J Clin Pharmacol Ther 2004; 42:232-9.
54. Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC 202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007; 96:29-37.
55. Vita M, Abdel-Rehim M, Nilsson C, Hassan Z, Skansen P, Wan H, et al. Stability, pKa and plasma protein binding of roscovitine. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 821:75-80.
56. Cervenkova K, Belejova M, Chmela Z, Rypka M, Riegrova D, Michnova K, et al. In vitro glycosidation potential towards olomoucine-type cyclin-dependent kinase inhibitors in rodent and primate microsomes. Physiol Res 2003; 52:467-74.
57. McClue SJ, Stuart I. Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (r-roscovitine) in vitro and in vivo. Drug Metab Dispos 2008; 36:561-70.
58. Rossi AG, Sawatzky DA, Walker A, Ward C, Sheldrake TA, Riley NA, et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med 2006; 12:1056-64.
59. Duffin R, Leitch AE, Sheldrake TA, Hallett JM, Meyer C, Fox S, et al. The CDK inhibitor, R-roscovitine, promotes eosinophil apoptosis by down-regulation of Mcl-1. FEBS Lett 2009; 583:2540-6.
60. Li L, Wang H, Kim J, Pihan G, Boussiotis V. The cyclin dependent kinase inhibitor (R)-roscovitine prevents alloreactive T cell clonal expansion and protects against acute GvHD. Cell Cycle 2009; 8:1794-802.
61. Yu C, Rahmani M, Dai Y, Conrad D, Krystal G, Dent P, et al. The lethal effects of pharmacological cyclindependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res 2003; 63:1822-33.
62. Wellwood J, Taylor K. Central nervous system prophylaxis in haematological malignancies. Intern Med J 2002; 32:252-8.
63. Sallam H, Jimenez P, Song H, Vita M, Cedazo-Minguez A, Hassan M. Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1/2 in the rat brain. Pharmacol Res 2008; 58:32-7.
64. Nouws JF. Pharmacokinetics in immature animals: A review. J Anim Sci 1992; 70:3627-34.
65. Rich KJ, Boobis AR. Expression and inducibility of P450 enzymes during liver ontogeny. Microsc Res Tech 1997; 39:424-35.
66. Alcorn J, McNamara PJ. Pharmacokinetics in the newborn. Adv Drug Deliv Rev 2003; 55:667-86.
67. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349:1157-67.
68. Butt AM, Jones HC, Abbott NJ. Electrical resistance across the blood-brain barrier in anaesthetized rats: A developmental study. J Physiol 1990; 429:47-62.
69. Zheng YL, Li BS, Kanungo J, Kesavapany S, Amin N, Grant P, et al. Cdk5 Modulation of mitogenactivated protein kinase signaling regulates neuronal survival. Mol Biol Cell 2007; 18:404-13.
70. Nikolic M, Tsai LH. Activity and regulation of p35/ Cdk5 kinase complex. Methods Enzymol 2000; 325:200-13.
71. Patrick GN, Zhou P, Kwon YT, Howley PM, Tsai LH. p35, the neuronal-specific activator of cyclindependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway. J Biol Chem 1998; 273:24057-64.
72. Kesavapany S, Amin N, Zheng YL, Nijhara R, Jaffe H, Sihag R, et al. P35/cyclin-dependent kinase 5 phosphorylation of ras guanine nucleotide releasing factor 2 (RasGRF2) mediates rac-dependent extracellular signal-regulated kinase 1/2 activity, altering RasGRF2 and microtubule-associated protein 1b distribution in neurons. J Neurosci 2004; 24:4421-31.
73. Meijer L, Raymond E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res 2003; 36:417-25.
74. Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009; 113:2637-45.
75. Daldrup-Link HE, Link TM, Rummeny EJ, August C, Konemann S, Jurgens H, et al. Assessing permeability alterations of the blood-bone marrow barrier due to total body irradiation: In vivo quantification with contrast enhanced magnetic resonance imaging. Bone Marrow Transplant 2000; 25:71-8.
76. Bhatia M, Militano O, Jin Z, Figurski M, Shaw L, Moore V, et al. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2010; 16:333-43.
77. Burger DM, Verweel G, Rakhmanina N, Verwey- Van Wissen CP, La Porte CJ, Bergshoeff AS, et al. Age-dependent pharmacokinetics of lamivudine in HIV-infected children. Clin Pharmacol Ther 2007; 81:517-20.
78. Hassan M, Ljungman P, Bolme P, Ringden O, Syruckova Z, Bekassy A, et al. Busulfan bioavailability. Blood 1994; 84:2144-50.
79. Hassan M, Oberg G, Bekassy AN, Aschan J, Ehrsson H, Ljungman P, et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 1991; 28:130-4.
80. Palle J, Frost BM, Gustafsson G, Hellebostad M, Kanerva J, Liliemark E, et al. Etoposide pharmacokinetics in children treated for acute myeloid leukemia. Anticancer Drugs 2006; 17:1087-94.
81. Palle J, Frost BM, Petersson C, Hasle H, Hellebostad M, Kanerva J, et al. Thioguanine pharmacokinetics in induction therapy of children with acute myeloid leukemia. Anticancer Drugs 2009; 20:7-14.